vs
Prenetics Global Ltd（PRE）与RAPID MICRO BIOSYSTEMS, INC.（RPID）财务数据对比。点击上方公司名可切换其他公司
RAPID MICRO BIOSYSTEMS, INC.的季度营收约是Prenetics Global Ltd的2.6倍（$11.3M vs $4.3M）
Prenetics是一家总部位于中国香港的健康科学企业，业务辐射美国地区，专注于癌症等疾病的早期筛查、预防与干预诊疗，致力于帮助人们更早发现健康风险，助力提升相关疾病的治疗效果，推动肿瘤等重疾的早防早治，守护公众健康。
RAPID MICRO BIOSYSTEMS, INC. 是生命科学领域的技术企业，专注于为生物制药厂商、合同研发生产机构等客户提供自动化微生物检测及质控解决方案，可大幅缩短检测周期、提升检测精度，业务覆盖北美、欧洲、亚太等全球核心市场。
PRE vs RPID — 直观对比
营收规模更大
RPID
是对方的2.6倍
$4.3M
损益表 — Q3 2023 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $4.3M | $11.3M |
| 净利润 | — | $-12.5M |
| 毛利率 | 44.9% | — |
| 营业利润率 | -396.2% | -108.2% |
| 净利率 | — | -110.8% |
| 营收同比 | — | 37.3% |
| 净利润同比 | — | -29.3% |
| 每股收益（稀释后） | — | $-0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRERPID
| Q4 25 | — | $11.3M | ||
| Q3 25 | — | $7.8M | ||
| Q2 25 | — | $7.3M | ||
| Q1 25 | — | $7.2M | ||
| Q4 24 | — | $8.2M | ||
| Q3 24 | — | $7.6M | ||
| Q2 24 | — | $6.6M | ||
| Q1 24 | — | $5.6M |
净利润PRERPID
| Q4 25 | — | $-12.5M | ||
| Q3 25 | — | $-11.5M | ||
| Q2 25 | — | $-11.9M | ||
| Q1 25 | — | $-11.3M | ||
| Q4 24 | — | $-9.7M | ||
| Q3 24 | — | $-11.3M | ||
| Q2 24 | — | $-12.6M | ||
| Q1 24 | — | $-13.3M |
营业利润率PRERPID
| Q4 25 | — | -108.2% | ||
| Q3 25 | — | -145.1% | ||
| Q2 25 | — | -167.3% | ||
| Q1 25 | — | -161.8% | ||
| Q4 24 | — | -124.5% | ||
| Q3 24 | — | -158.3% | ||
| Q2 24 | — | -202.1% | ||
| Q1 24 | — | -254.4% |
净利率PRERPID
| Q4 25 | — | -110.8% | ||
| Q3 25 | — | -146.8% | ||
| Q2 25 | — | -163.3% | ||
| Q1 25 | — | -156.3% | ||
| Q4 24 | — | -117.6% | ||
| Q3 24 | — | -148.9% | ||
| Q2 24 | — | -190.1% | ||
| Q1 24 | — | -237.4% |
每股收益（稀释后）PRERPID
| Q4 25 | — | $-0.26 | ||
| Q3 25 | — | $-0.26 | ||
| Q2 25 | — | $-0.27 | ||
| Q1 25 | — | $-0.26 | ||
| Q4 24 | — | $-0.22 | ||
| Q3 24 | — | $-0.26 | ||
| Q2 24 | — | $-0.29 | ||
| Q1 24 | — | $-0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $20.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $33.2M |
| 总资产 | — | $74.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PRERPID
| Q4 25 | — | $20.0M | ||
| Q3 25 | — | $18.9M | ||
| Q2 25 | — | $18.3M | ||
| Q1 25 | — | $18.9M | ||
| Q4 24 | — | $16.9M | ||
| Q3 24 | — | $22.0M | ||
| Q2 24 | — | $37.1M | ||
| Q1 24 | — | $22.4M |
股东权益PRERPID
| Q4 25 | — | $33.2M | ||
| Q3 25 | — | $44.3M | ||
| Q2 25 | — | $54.5M | ||
| Q1 25 | — | $65.5M | ||
| Q4 24 | — | $75.4M | ||
| Q3 24 | — | $84.4M | ||
| Q2 24 | — | $94.6M | ||
| Q1 24 | — | $105.9M |
总资产PRERPID
| Q4 25 | — | $74.9M | ||
| Q3 25 | — | $84.4M | ||
| Q2 25 | — | $75.6M | ||
| Q1 25 | — | $85.4M | ||
| Q4 24 | — | $98.2M | ||
| Q3 24 | — | $105.8M | ||
| Q2 24 | — | $117.1M | ||
| Q1 24 | — | $127.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-3.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-3.3M |
| 自由现金流率自由现金流/营收 | — | -29.6% |
| 资本支出强度资本支出/营收 | — | 0.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-31.9M |
8季度趋势，按日历期对齐
经营现金流PRERPID
| Q4 25 | — | $-3.2M | ||
| Q3 25 | — | $-9.1M | ||
| Q2 25 | — | $-9.7M | ||
| Q1 25 | — | $-9.1M | ||
| Q4 24 | — | $-9.9M | ||
| Q3 24 | — | $-8.6M | ||
| Q2 24 | — | $-10.1M | ||
| Q1 24 | — | $-15.5M |
自由现金流PRERPID
| Q4 25 | — | $-3.3M | ||
| Q3 25 | — | $-9.1M | ||
| Q2 25 | — | $-10.1M | ||
| Q1 25 | — | $-9.4M | ||
| Q4 24 | — | $-10.0M | ||
| Q3 24 | — | $-8.8M | ||
| Q2 24 | — | $-10.6M | ||
| Q1 24 | — | $-16.1M |
自由现金流率PRERPID
| Q4 25 | — | -29.6% | ||
| Q3 25 | — | -116.4% | ||
| Q2 25 | — | -138.6% | ||
| Q1 25 | — | -130.2% | ||
| Q4 24 | — | -121.8% | ||
| Q3 24 | — | -116.0% | ||
| Q2 24 | — | -159.8% | ||
| Q1 24 | — | -287.1% |
资本支出强度PRERPID
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 5.0% | ||
| Q1 25 | — | 4.4% | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | — | 2.9% | ||
| Q2 24 | — | 6.9% | ||
| Q1 24 | — | 10.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRE
暂无分部数据
RPID
| Products | $9.3M | 83% |
| Services | $2.0M | 17% |
